Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
ESC 2018 – J&J not downhearted after Xarelto stumbles
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
FDA’s flashing green light boosts novel drug approvals
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.
